Skip to main content
For laboratory research use only. Not for human or veterinary use.
Free shipping on every order
10% off your first order · code FIRST10
GLP-1 family

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frías JP, Davies MJ, Rosenstock J, et al. · N Engl J Med · 2021
PMID: 34170647 · DOI: 10.1056/NEJMoa2107519
Summary

40-week phase 3 open-label randomized trial (SURPASS-2) in 1879 adults with type 2 diabetes comparing tirzepatide 5/10/15 mg vs semaglutide 1 mg, both subcutaneous once weekly. Primary endpoint: change in HbA1c from baseline.

Read the full citation on PubMed

Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.

Compounds referenced in this study
  • GLP-2 T
    Dual-receptor incretin class agonist studied in metabolic-pathway research.
    View product →
  • GLP-1 S
    Single-receptor incretin class agonist studied in incretin-pathway metabolic research.
    View product →
Guides covering this compound
More GLP-1 family citations
Browse the catalog